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Aim: Although multiple sclerosis (MS) can cause almost any neurological symptom, headaches are considered unusual. Studies
investigating the relationship between the 2 conditions have produced conflicting results. The primary aim of this study was to test
whether there was a difference between patients with MS (Group 1) and the control group (Group 2, patients with psoriasis and
myasthenia gravis, diseases not affecting the central nervous system) in terms of the prevalence and types of primary headache.
Materials and methods: A total of 139 patients with MS and 59 patients in the control group were included. The patients underwent
a complete neurological examination and functional systems were assessed according to the functional system scores of Kurtzke. A
semistructured interview guided by a questionnaire about headache was applied.
Results: We found the life-long prevalence of primary headaches as 74.8% in patients with MS and as 71.2% in the control group. The
prevalence of migraine and tension-type headaches did not show a significant difference between the 2 groups before the disease (P =
0.43), after the onset of disease (P = 0.18), or during the attack (P = 0.097).
Conclusion: MS does not increase the prevalence of headaches, and headache types do not show any difference between MS patients
and the control group.
Key words: Multiple sclerosis, headache, prevalence, migraine, tension-type headache

1. Introduction
Multiple sclerosis (MS) is an immune-mediated chronic
disorder of the central nervous system (CNS) in
young people, characterized by a spatial and temporal
dissemination of the pathological process. Multiple areas
of inflammation, demyelination, and glial sclerosis are
observed in the white matter. Various symptoms and signs
occur due to the affected areas in the brain and the spinal
cord (1).
Headaches are not a symptom of MS. The first article on
the relationship between MS and headaches was published
in 1952 (2). The life-long prevalence of headaches in
patients with MS has been reported as ranging from 4%
to 64% (3–10). The rate of migraine and of tension-type
headaches in all MS patients with headache has been
reported at 20%–70% and 21%–48% , respectively (4–11).
Despite the presence of publications reporting that the
onset of headaches could be concomitant with the onset
of MS symptoms and that headaches can show recurrence
during the attack period in patients with relapsing
remitting MS (RRMS), there are opposite suggestions in
English-based literature (3–5,11–22). Moreover, although
* Correspondence: drmsorgun79@yahoo.com.tr
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some studies showed that RRMS could be correlated with
migraines, this issue could not be confirmed with other
studies (3–5,8–22). In another study, it was suggested
that deregulation of the serotonergic system may also be
involved in the pathogenesis of MS as well as migraines
(13). It was emphasized in a recent study that a stabbing
headache was more common during the attack, and
migraine and tension-type headaches were more common
during remission in patients with RRMS (9). There are
publications suggesting that the frequency of headaches
and occurrence of new headaches is increased by the use
of interferon-β in the treatment of MS (6,7,23–25).
It was not known if headache frequency and
characteristics are similar in patients with MS (which is an
inflammatory disease of the CNS) to headaches in patients
with other chronic diseases that do not involve the CNS.
Knowing this may provide clues about the pathogenesis of
headaches in MS.
The primary aim of this study was to test whether
there was a difference between patients with MS (Group
1) and the control group (Group 2, patients with psoriasis
and myasthenia gravis, diseases not affecting the central
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nervous system) in terms of the prevalence and types of
primary headache. We also compared the relationship
between the onset of primary headaches and of the diseases
between the groups, as well as the relationship between
the onset of primary headaches and of the attacks. The
second aim of this study was to find whether headaches
in various types of MS (RRMS, secondary progressive MS
(SPMS), primary progressive MS (PPMS), and progressive
relapsing MS (PRMS)) were similar; if the migraines in
patients with RRMS were more frequent; if the headache
types during the remission period and during attacks were
similar; and if the presence of depression had any impact
on these parameters.
2. Materials and methods
Patients presenting to the Multiple Sclerosis Clinic of the
Ankara University Faculty of Medicine, Department of
Neurology, from June 2005 to June 2008 were enrolled
in this study (Group 1). Patients with the diagnosis of
psoriasis and myasthenia gravis who were administered
to our hospital in same period constituted the control
group (Group 2). The study was approved by the Ethics
Committee of the Ankara University Faculty of Medicine.
All patients gave written consent for the study.
The inclusion criteria were: having a definitive diagnosis
of MS, age between 18 and 55, and giving consent. The
exclusion criteria were: having any disease which mimics
MS (including systemic lupus erythematosus and Behçet’s
disease) and administration of megadoses of steroids prior
to the assessment.
The date of diagnosis, other acute and chronic diseases,
and types and duration time of all medications were

recorded. Furthermore, the patients were questioned
regarding the onset of the headache, i.e. whether it began
before the onset of symptoms of the disease, after the
diagnosis of the disease, or during attacks of the disease. A
neurological examination was performed for each patient.
Functional system involvement was assessed using the
Kurtzke Functional System Scale for each system and the
expanded disability state score (EDSS) was calculated.
A detailed structured questionnaire on headaches was
given to all patients in face-to-face interviews. Headaches
were classified using the 2004 diagnostic criteria of the
International Headache Society (26). All patients were
examined with the Mini Mental State Test. The patients
were then asked to complete the Hamilton Anxiety Scale
and the Hamilton Depression Scale.
2.1. Statistics
The group rates were compared using the chi-square test,
and the means were compared using the Student t-test.
Multiple logistic regression analysis was used to determine
the independent risk factors. All variables with a P-value of
<0.25 in univariate analyses were included in the multiple
logistic regression analysis. P < 0.05 was considered
statistically significant. Statistical analysis was performed
using SPSS 11.5 (SPSS Inc., Chicago, IL, USA).
3. Results
In our study, 139 patients with MS and 59 patients in the
control group (52 patients with psoriasis and 7 patients
with myasthenia gravis) were included. Of the patients with
MS, 96 (69.1%) were female and 43 (30.9%) were male. Of
the control group, 37 (62.7%) were female and 22 (37.3%)
were male (Table 1); there was no significant difference

Table 1. Demographic features and disease-related parameters in the MS and control groups.
MS
n = 139

Control
n = 59

P

37 ± 10.2

37 ± 11.4

0.878

Female

96 (69.1)

37 (62.7)

Male

43 (30.9)

22 (37.3)

Disease duration, median (min–max)

6.7 (1–29)

13.8 (1–41)

0.001*

Relapsing-remitting type, n (%)

129 (92.8)

55 (93.2)

0.917

Number of the diseases’ attacks, median (min–max)

4 (1–20)

7.6 (1–30)

0.001*

EDSS median (min–max)

2 (0–9)

0

0.000*

HDS, mean ± SD

4.36 ± 4.5

3.30 ± 4.4

0.245

HAS, mean ± SD

3.49 ± 3.6

2.2 ± 3.2

0.073

Age, years, mean ± SD
Sex, n (%)

0.384

SD: Standard deviation. HDS: Hamilton Depression Scale. HAS: Hamilton Anxiety Scale. *: Statistically significant.
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between the groups (P = 0.4). The mean age of patients
with MS was 37 ± 10 years (range = 18–64). The mean age
in the control group was 37 ± 11 years (range = 17–55).
The difference between the 2 groups was not significant (P
= 0.88). The mean number of attacks in patients with MS
was 4 ± 3 (range = 1–20), while in the control group it was
7.6 ± 6.7 (range = 1–30). The difference was significant (P
= 0.001). The median EDSS score for patients with MS was
2 (range = 0–9) (Table 1).
Among the patients with MS, 109 (78.4%) cases were
RRMS, 15 (10.8%) were SPMS, 10 (7.2%) were PPMS,
and 5 (3.6%) were PRMS. Of the patients with psoriasis,
48 (81.4%) patients had activation with intervals, and
4 (6.8%) had continuous lesions. Of the patients with
myasthenia gravis, all were in remission (11.9%). Of the
patients with MS, 64 (46%) were in the attack period and
75 (54%) were in remission; of the patients in the control
group, 27 (45.8%) were in the attack period and 32 (54.2%)
were in remission. There was no difference between the 2
groups in terms of having attacks (P = 0.97). There was
other chronic disease in 47 (33.8%) patients with MS and
in 13 (22%) patients in the control group (P = 0.01).
Of the patients with MS, 16 (11.5%) were using
interferon beta-1a (44 µg), 11 (7.9%) were using glatiramer
acetate, 15 (10.8%) were using interferon beta-1b, 17
(12.2%) were using interferon beta-1a 6 MIU, and 80
(57.6%) were not using any immunomodulator drugs. The
mean score of the Hamilton Depression Scale was 4.36
± 4.54 (range = 0–23) and 3.30 ± 4.19 (range = 0–17) in
Groups 1 and 2, respectively; the difference between the
groups was not significant (P = 0.25). The mean score
of the Hamilton Anxiety Scale was 3.49 ± 3.61 (range =

0–23) and 2.2 ± 3.26 (range = 0–10) in Groups 1 and 2,
respectively; the difference between the groups was not
significant (P = 0.07). Patients with a score of ≥8 on the
Hamilton Depression Scale were accepted as having
depression; 17.4% of patients in Group 1 and 20% of
patients in Group 2 had depression; the difference between
the groups was not significant (P = 0.72).
Of the patients with MS, 35 (25.2%) did not have
headache before or after the disease; the same was true for 17
(28.8%) of the patients in the control group. Of the patients
with MS, 69 (49.6%) had the onset of headache before the
disease, and 35 (25.2%) had the onset of headache after the
disease. In the control group, 20 (33.9%) patients had the
onset of headache before the disease and 22 (37.3%) had
the onset of headache after the disease, and the difference
between the groups was not significant (P = 0.1). Of the
patients with MS, 47 (33.8%) described headaches during
the attack, and in the control group, 18 (30.5%) described
headaches during the attack, and the difference between
the groups was not significant (P = 0.7).
We compared the headache types in the MS group and
the control group before the disease, during the disease,
and during the attack (Table 2). As the number of patients
with probable migraines was few, we included these
patients in the migraine group. As the number of patients
with stabbing headache was few, we did not include them
in the statistical analysis. Therefore, statistical analysis was
performed only for migraine and tension-type headaches
(Table 3). The prevalence of migraine and tension-type
headaches did not show a significant difference between
the 2 groups before the disease (P = 0.43), after the onset of
disease (P = 0.18), or during the attack (P = 0.097).

Table 2. Headache types in the MS and control groups.
Headache types
TTH,

Migraine,

Probable migraine,

Stabbing Headache,

No headache,

Total

n (%)

n (%)

n (%)

n (%)

n (%)

MS

34 (24.5)

30 (21.6)

4 (2.9)

1 (0.7)

70 (50.4)

139

Control

8 (13.6)

11 (18.6)

1 (1.7)

-

39 (66.1)

59

MS

50 (36.0)

35 (25.2)

8 (5.8)

-

46 (33.1)

139

Control

16 (27.1)

21 (35.6)

2 (3.4)

2 (3.4)

18 (30.5)

59

MS

22 (17.1)

18 (14)

5 (3.9)

-

92 (66.2)

139

Control

4 (7.3)

12 (21.8)

-

-

41 (69.5)

59

Before the disease

During the disease

During the attack

TTH: Tension-type headache.
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Table 3. Prevalence of migraine and tension-type headache in the MS and control groups.
TTH,
n (%)

Migraine*,
n (%)

Total

P

MS

34 (50)

34 (50)

68

0.43

Control

8 (40)

12 (60)

20

MS

50 (53.8)

43 (46.2)

93

Control

16 (41.0)

23 (59)

39

MS

22 (48.9)

23 (51.1)

45

Control

4 (25)

12 (75)

16

Headache types
Before the disease

During the disease
0.182

During the attack
0.097

TTH: Tension-type headache. *: Including probable migraine.

The onset time of the headaches regarding MS course
is presented in Table 4. As the number of patients in each
progressive course of MS (including SPMS, PPMS, and
PRMS) was few, we grouped all of them under the title of

“progressive MS” and compared them to the RRMS group
(Table 5). The prevalence of tension-type headaches before
and after the onset of disease did not show a significant
difference between RRMS and progressive MS groups

Table 4. The onset time and types of headache in different MS subtypes.
TTH,
n (%)

Migraine,
n (%)

Probable migraine,
n (%)

Stabbing Headache,
n (%)

No headache,
n (%)

RRMS

26 (23.9)

28 (25.7)

3 (2.8)

1(0.9)

51 (46.8)

SPMS

3 (20)

-

-

-

12 (80)

PPMS

2 (40)

1 (20)

-

-

2 (40)

PRMS

3 (30)

1 (10)

1 (10)

-

5 (50)

RRMS

39 (50.6)

32 (29.4)

6 (5.5)

-

32 (29.4)

SPMS

6 (40)

1 (6.7)

1 (6.7)

-

7 (46.7)

PPMS

2 (40)

1 (20)

-

-

2 (40)

PRMS

3 (30)

1 (10)

1 (10)

RRMS

16 (14.7)

17 (15.6)

5 (4.6)

-

71 (65.1)

SPMS

4 (26.7)

-

-

-

11 (73.3)

PPMS

2 (40)

1 (20)

-

-

2 (40)

Headache types
Before the disease

During the disease

5 (50)

During the attack

TTH: Tension-type headache.
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Table 5. The onset time of migraines and tension-type headaches in the RRMS and progressive MS groups.
TTH,
n (%)

Migraine*,
n (%)

Total

RRMS

26 (45.6)

31 (54.4)

57

Progressive MS

8 (72.7)

3 (27.3)

11

RRMS

39 (50.6)

38 (49.4)

77

Progressive MS

11 (68.8)

5 (31.3)

16

RRMS

16 (42.1)

22 (57.9)

38

SPMS+PRMS

6 (85.7)

1 (14.3)

7

Headache types

P

OR

0.1

3.18 (0.8–13)

0.1

2.14 (0.8–13)

0.047*

8.25 (0.9–75.4)

Before the disease

During the disease

During the attack

*: Including probable migraine.

(P = 0.1 and P = 0.1, respectively). Migraines were more
prevalent during the attack in the RRMS group compared
to the group with progressive MS with attacks (P = 0.047).
We tested whether there was similarity between types
of headache that began after the onset of MS and that
began during relapses (if it was seen also in relapses). In
cases where patients had tension-type headaches after the
onset of MS as well as during MS attacks, 90.9% of MS
patients had tension-type headaches during their relapse
periods, too. Only 9.1% of those patients had migraines
during relapse periods. All patients with migraines that
began after the onset of MS, if they had headaches during
their relapse period, had migraines. There was a significant
relationship between types of headaches that began after
the onset of MS and types seen during relapses, too (P =
0.000). A similar relationship was also found in the control
group (P = 0.000).
In the multiple regression analysis, it was found that
the age, sex, and immunomodulatory drug use in the MS
group did not have any effect on headaches; it was found
that the presence of depression was an independent risk
factor for headache (OR = 5.9, 95% CI (1.7–20.6), P =
0.002). There was no significant relationship between
headaches and depression in the control group (P = 1).
4. Discussion
In their prospective study with no control group, D’Amico
et al. found that the life-long prevalence of primary
headaches in 137 patients with MS was 57.7% (3). In
another prospective study with no control group, Villani
et al. reported that the life-long prevalence of primary
headaches in 102 patients with MS was 61.8% (12). In
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yet another prospective study without a control group
undertaken by Boneschi et al., the life-long prevalence
of headache was found to be 35.5% in 428 patients with
MS (24). Ergün et al. found that the prevalence of primary
headache was 73.5% in 44 patients with RRMS during
remission (9).
In the majority of controlled studies published to date,
the prevalence of headaches has been found to be higher in
patients with MS compared to the control group (4,6,15).
There has been only one study stating that the prevalence
of headaches in patients with MS is equal to that of the
general population (7).
We found the life-long prevalence of primary headaches
to be 74.8% in patients with MS and 71.2% in the control
group. Our prevalence was the highest in the literature.
Even more striking was the fact that the headache
prevalence in the control group was also as high as that of
the MS group. Our control group was made up of patients
with no disability, having psoriasis or myasthenia gravis,
and having relapse and remission periods like MS. The
high headache prevalence in the control group suggested
that the life-long prevalence of primary headaches is high
not only in MS, but in other chronic conditions as well.
Further studies with larger patient numbers are needed to
clarify this issue.
Freedman and Gray reviewed the records of 1113
patients with MS who were followed-up with for 20 years,
and they found that 17 cases out of 44 with vascular-type
headaches began after the onset of MS (5). Boneschi et
al. reported in their study with 428 patients with MS that
62.5% of patients with tension-type headaches and 77.6%
of patients with migraines had these headaches before the
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onset of MS (24). Doi et al. reported that 32.3% of patients
had the onset of headaches after the diagnosis of MS (8). In
our patients with MS, 49.6% experienced headaches before
the onset of clinical signs of disease; this rate was 33.9%
in the control group. The onset of headaches occurred
after the onset of disease in 25.2% of patients with MS
and in 37.3% of the control group patients. The onset of
headache before disease was more frequent in the MS
group compared to the control group (P = 0.042; OR =
1.9). In conclusion, MS does not increase the prevalence of
headaches after the onset of MS.
The prevalence of migraine and tension-type headaches
in MS patients has been reported as being similar to that
of control groups in previous studies (4,6–8). The type and
onset time of headaches in patients with MS and the control
group were similar in our study, too. We suggest that the
headache types do not show any difference between MS
and control groups, a finding consistent with the literature.
We found a significant relationship between types of
headaches that were attack-related and headaches that
were seen in the remission phase in both the MS patients
and the control group (Table 2). Thus, we can conclude
that the type of headache seen during the exacerbations of
MS, and of other diseases that do not affect the CNS, is the
same type as the headache seen during remission.
There are publications suggesting that migraines are
more prevalent in patients with RRMS, and that tension
type of headache is more prevalent in patients with
progressive MS (3,12). However, there are also publications
suggesting the lack of such an association (8,15). Consistent
with these publications, the prevalence of migraine and
tension-type headaches that began before or after the
onset of MS did not show any difference between RRMS
and progressive MS groups. However, the prevalence of
attack-related migraines during relapse periods was 57.9%
and 14.3% in patients with RRMS and progressive MS,
respectively; the prevalences were 42.1% and 85.7% for
attack-related tension-type headaches, respectively; and
the difference between the 2 groups was significant (P
= 0.047). In another study from Turkey, it was reported
that a stabbing-type headache was common in the attack
period; however, we could not find a similar result (Table
2). We concluded that migraines were more prevalent in
patients with RRMS, and tension-type headaches were
more prevalent in patients with progressive MS during
relapse periods.
Rolak et al. reported that headaches began 7 years
before the onset of MS, and that in 7 patients, the headaches
started (tension-type headache in 3 patients, migraine in
4 patients) with the first symptoms of MS; however, the
headache did not occur during the next attacks in the
patients except in 1 patient (15). Freedman and Gray
reported in their study that migraines began concurrently

with MS in 12 of 44 patients with MS; hence, neurological
signs in some of these patients were attributed to migraine
vasospasm, and in 6 patients in whom there was an
already existing migraine, the migraine was said to have
accompanied the first MS attack. These authors suggested
that there was vascular headache in 4% of patients with
MS, which could be attributed to demyelination (5). Gee et
al. reported that in 27% of 154 patients with headaches and
MS, the headache occurred during the first MS symptoms
or during an attack (16). Vacca et al. stated that in 69.67%
of 122 patients, the headache began before MS, and that
the onset of MS did not change the headache and that the
severity of the headache increased following the onset of
MS only in 13 patients (4). In a study by Ergün et al., it was
found that in 44 patients with RRMS, migraines (41.2%)
and tension-type headaches (20.6%) were common in
remission, whereas stabbing headaches (27.8%) were
common in the relapse period (9). We did not have any
patient with MS in whom a headache was seen as a first
attack. In 33.8% of our patients with MS, there was a
headache during the MS attack. In 30.5% of the control
patients, there was a headache during the exacerbation
of their diseases. We concluded that the presence of
headaches during the exacerbation was not specific for
MS; there was a similar finding for the other diseases.
In our study, we found that the presence of depression
in patients with MS increased the risk for headache 6-fold.
We found no significant relationship between the other
parameters (sex, age, chronic drug use, immunomodulator
drug use, other chronic diseases, functional system
involvement, EDSS, duration of disease, and age at onset
of disease) and headache. Contrary to MS, there was no
relationship between depression and headache in the
control group. The life-long prevalence of depression in
patients with MS was reported as 22% to 54% (27). In
our patients with MS, 17.4% had depression, whereas
20% of the control patients had depression. We think
that headaches are more common in MS patients with
depression than in MS patients without depression.
Our study has some limitations. Although the groups
were homogeneous in terms of age, sex, and disease
duration and course, the higher number of attacks in the
control group compared to the MS group may have caused
a higher prevalence of headache in the control group and
thus no difference between the groups. It was suggested
that the proinflammatory immune response may be
responsible for the pathogenesis of headache (28,29).
Patients with psoriasis were the majority of the patients in
the control group. Proinflammatory immune response is
predominant in patients with psoriasis, similar to MS (30–
37). Based on our finding that headaches were frequent
in the control group, we can suggest that if this was to be
related to the proinflammatory immune response, then the
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headaches in MS would not be related to demyelination
plaques. Therefore, further controlled studies are needed
with larger samples in which patients with MS would be
compared to patients with diseases not affecting the CNS
(such as psoriasis) as the control group, and in which the
frequency of attacks are homogeneous between the groups.
In conclusion, we could not find a significant difference
for the frequency of headaches between MS and control
groups; we think that the previous hypothesis suggesting
that demyelination in the CNS in MS may be the cause
of headache is invalid. There was no significant time
relationship between the onset of headache and the onset
of disease either in patients with MS or in the control
group. The similarity between the types of headache in
patients with MS and in the control group and the lack of
any significant relationship between the disease course and
headache type suggests that there is no type of headache

that is specific to MS or its course. Contrary to previous
publications, we can say that migraine is not more common
in the remission period of RRMS. The probability of
headache during the attack period of MS is high; however,
this is not specific for MS; the same high rate is also current
in the control group. Furthermore, the type of headache
seen during the attack period is not different from that seen
during remission. Finally, depression increases the risk of
headache in patients with MS.
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